atorvastatin / Generic mfg. - LARVOL DELTA

Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort. (PubMed, Front Cardiovasc Med) - "In the moderate-intensity group, rosuvastatin (adjusted HR 1.07, 95% CI 1.01-1.14), pravastatin (HR 1.19, 95% CI 1.02-1.38), and simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin, while fluvastatin and pitavastatin showed no significant differences. In this nationwide secondary prevention cohort, the risk of NODM differed across individual statins despite comparable cardiovascular outcomes. These findings suggest that the diabetogenic effect of statins may be agent-specific rather than a uniform class effect, highlighting the importance of individualized statin selection balancing metabolic and cardiovascular benefits."

Journal • Reimbursement • US reimbursement • Atherosclerosis • Cardiovascular • CNS Disorders • Diabetes • Metabolic Disorders

CHORMONE: The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, muscle morphology, vitamin D, the immune system and related diseases such as depression and osteoporosis (clinicaltrialsregister.eu) - P4 | N=250 | Recruiting | Sponsor: Medical University Of Vienna | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Depression • Dyslipidemia • Mood Disorders • Osteoporosis • Psychiatry • Rheumatology

SHORT-TERM EFFICACY AND LONG-TERM FOLLOW-UP OBSERVATION OF ROXADUSTAT IN TREATING RENAL ANEMIA IN ELDERLY PATITENTS WITH NDD-CKD (ISN-WCN 2026) - "Lipid changes in patients using atorvastatin and outcomes of all patients, including major clinical events, were also observed.Results A total of 67 NDD-CKD stages 3-5 patients were included, with a mean age of 75.3±9.0 years. For CKD stage 5 patients, increasing the initial dose by one step may help achieve early hemoglobin targets. Elderly patients need enhanced monitoring to avoid large fluctuations in hemoglobin levels."

Clinical • Anemia • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Diabetes • Dyslipidemia • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Infectious Disease • Metabolic Disorders • Myocardial Infarction • Nephrology • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Thrombosis • Type 2 Diabetes Mellitus

BEYOND DIABETES: WHEN NEPHROTIC SYNDROME IS NOT DIABETIC NEPHROPATHY IN A PATIENT WITH LONG STANDING TYPE TWO DIABETES MELLITUS (ISN-WCN 2026) - "Her medications included biphasic human insulin 20 units in the morning and 12 units at night, empagliflozin 10mg daily, vildagliptin/metformin 50/500 once daily, telmisartan 40 mg once daily, and atorvastatin 80 mg at night .Glycemic control was sub-optimal (HbA1c 7.8%) and fundoscopy revealed no evidence of diabetic or hypertensive retinopathy.She reported intermittent joint pains without arthritis or constitutional symptoms.On examination, she was hemodynamically stable with bilateral pedal edema...There was no evidence of diabetic nephropathy, confirming primary membranous nephropathy.The patient was initiated on the modified Ponticelli regimen, consisting of oral corticosteroids alternating with oral cyclophosphamide...A high index of suspicion, serologic workup, and renal biopsy helped uncover primary membranous nephropathy in a diabetic patient, allowing timely immunosuppressive therapy with promising early response. Clinicians should, therefore, maintain..."

Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Diabetic Retinopathy • Glomerulonephritis • Hypertension • Immunology • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Nephrology • Orthopedics • Renal Disease • Retinal Disorders • Type 2 Diabetes Mellitus

SGLT- 2I: "CAN BE A HOPE FOR PERITONEAL DIALYSIS PATIENTS." (ISN-WCN 2026) - "At baseline, his blood pressure was 168/88 mmHg with telmisartan 80 mg/day, amlodipine 10 mg /day, prazosin 10 mg/day, and torsemide 100 mg/day. Other medications were dapagliflozin 10mg/day, linagliptin 5 mg/day, sodium bicarbonate 1000 mg twice daily, insulin, atorvastatin 10mg/day, and aspirin 75 mg/day...There was no hospitalization in this follow-up period.Conclusion As the drug is well tolerated and no adverse effects are noted in this 35-month follow-up, we may hope to use this drug in some dialysis-dependent patients. The findings in this case report need to be confirmed in a large prospective study with a longer follow-up period."

Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

ADJUNCTIVE HEMOADSORPTION WITH DNA 230 IN SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS WITH MULTIORGAN INVOLVEMENT: A CASE REPORT (ISN-WCN 2026) - "She exhibited SLE activity in renal, mucocutaneous, serosal, hematologic, and immunologic domains.She was started on ceftriaxone, paracetamol, N-acetylcysteine, hydrocortisone, calcium + vitamin D, losartan, and atorvastatin. She was discharged stable on day 25 on tapering corticosteroids with a scheduled renal biopsy.Renal, liver and inflammatory markersConclusion This case highlights the potential role of DNA 230 hemoadsorption as an adjunct to standard immunosuppression and dialysis in severe lupus with multiorgan involvement. By facilitating removal of cytokines and inflammatory mediators, hemoadsorption may accelerate recovery and improve organ function during lupus flares."

Case report • Clinical • Acute Kidney Injury • Cardiovascular • CNS Disorders • Epilepsy • Glomerulonephritis • Heart Failure • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Metabolic Disorders • Nephrology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Systemic Lupus Erythematosus

IT AIN'T HYPERKALEMIA: ADULT-ONSET JAK2-POSITIVE POLYCYTHEMIA RUBRA VERA COMPLICATED BY THE DOUBLE WHAMMY OF CONCURRENT PSEUDOHYPERKALEMIA AND TRUE IATROGENIC DRUG-RELATED HYPONATREMIA (ISN-WCN 2026) - "We report the simultaneous and concurrent existence of pseudohyperkalemia and true hyponatremia in a now 73-yo male who was diagnosed with adult-onset polycythemia rubra vera in early 2016, and was subsequently treated with Hydroxyurea for several years, then was switched to Anagrelide and Ruxolitinib in more recent years.Methods Case Report.Results A now 73-year-old male was diagnosed in early 2016 with JAK2-positive polycythemia vera on bone marrow biopsy following the incidental finding of elevated hemoglobin and platelet counts on routine blood testing...Lipid profile was normal with LDL 77 mg/dL, Triglycerides 50 mg/dL, HDL 80 mg/dL on Atorvastatin 10 mg daily...We advised that subsequent potassium monitoring be carried out in plasma.On another front, there are rare reports that suggest that sodium and potassium levels in conditions of hyperleukocytosis go in opposite directions, being driven by various hypothesized mechanisms that may involve cell breakdown and..."

Clinical • Cardiovascular • Endocrine Disorders • Heart Failure • Hematological Disorders • Nephrology • Obstructive Sleep Apnea • Polycythemia Vera • Pruritus • Renal Disease • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Thrombocytosis • JAK2

IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED MINIMAL CHANGE DISEASE - A CASE OF SUCCESSFUL RECHALLENGE (ISN-WCN 2026) - "After progression on carboplatin and paclitaxel, she was subsequently started on pembrolizumab, and demonstrated clinical response after three cycles, the last given 2 weeks before presentation...Given the temporal association and favorable oncologic response to ICI therapy, the diagnosis of MCD was attributed to pembrolizumab.ICI therapy was discontinued, and the patient was treated with oral prednisone 60 mg daily (tapered over 24 days) and rituximab (anti-CD20 antibody) 1 g IV given 2 weeks apart. Supportive therapy included bumetanide 1 g IV twice daily, losartan 12.5 mg daily, and atorvastatin 10 mg daily...In two cases, MCD relapsed following ICI re-challenge while in the third case, MCD remission was maintained with daily low-dose prednisone. Here, we report the first successful ICI re-challenge in a patient with ICI-associated MCD using a short course of low-dose prednisone bridging, achieving sustained renal remission and durable anti-tumor response."

Checkpoint inhibition • Clinical • CNS Disorders • Dyslipidemia • Endometrial Cancer • Glomerulonephritis • Immunology • Oncology • Solid Tumor

Atorvastatin and left ventricular strain during anthracycline-based chemotherapy. (PubMed, Int J Cardiol) - P2 | "Atorvastatin decreased the odds of a significant decline in LV GCS, a predictor of adverse cardiac outcomes in patients undergoing anthracycline-based chemotherapy. Atorvastatin did not significantly attenuate the odds of a decline in LV GLS. (Clinical trial registration: NCT02943590; https://clinicaltrials.gov/study/NCT02943590)."

Journal • Cardiovascular • Hematological Malignancies • Lymphoma • Oncology

Old Molecules, New Hope: A Scoping Review and Bibliometric Analysis of Drug Repurposing for Lung Cancer. (PubMed, Chem Biol Interact) - "Frequently studied drugs included niclosamide, metformin, atorvastatin, and doxazosin, targeting pathways such as PI3K/AKT/mTOR, apoptosis, and autophagy. Progress in this field depends on integrating diverse methodologies and fostering interdisciplinary collaboration. As a next step, rigorous clinical trials are essential to confirm the efficacy and safety of promising repurposed agents in oncology."

Journal • Review • CNS Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Effect of blood lipid on myocardial injury in rats with myocardial infarction. (PubMed, Am J Transl Res) - "Alterations in blood lipid levels are closely associated with cardiac dysfunction and myocardial injury following AMI in vivo."

Journal • Preclinical • Cardiovascular • Dyslipidemia • Myocardial Infarction • CASP1 • CASP12 • CASP3 • TNNI3

Atorvastatin promotes lipid catabolism in colorectal cancer via FDFT1‒mediated inhibition of the PI3K/AKT pathway. (PubMed, Cell Commun Signal) - No abstract available

Journal • Colorectal Cancer • Oncology • Solid Tumor • FDFT1

Lipid Goal Achievement With Statins Among Statin-Naïve Indian Patients Undergoing Percutaneous Coronary Intervention. (PubMed, J Soc Cardiovasc Angiogr Interv) - "Only 41.1% and 42.5% of statin-naïve Indian patients undergoing PCI achieved lipid goals on statins at 1 and 6 months, suggesting a need for more intensive lipid-lowering strategies post-PCI. Rosuvastatin was marginally more efficacious than atorvastatin."

Journal • Acute Coronary Syndrome • Cardiovascular • Dyslipidemia

Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial. (PubMed, Sci Rep) - P2/3 | "Clinical trial number: NCT05563389 (https://register.clinicaltrials.gov/prs/beta/studies/S000CHKM00000052/recordSummary). The online version contains supplementary material available at 10.1038/s41598-026-41326-4."

Journal • Fibrosis • Gastroenterology • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Liver Failure • Musculoskeletal Pain • Nephrology • Pain • Renal Disease • CRP • NFKB1

PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes. (PubMed, Front Med (Lausanne)) - "According to the medical records, all patients were categorized into the Control group (n = 30, atorvastatin 20 mg QN) and the PCSK9i group (n = 30, evolocumab injection 140 mg Q2W in addition to atorvastatin). Multivariable regression analyses demonstrated the superior improvement in CAP and FLI observed with PCSK9-i is independent of concomitant sodium-glucose co-transporter 2 inhibitor (SGLT-2i) therapy. PCSK9i effectively reduced hepatic steatosis surrogate scores (FLI, CAP) and lipid levels (TC, LDL-C) in patients with MAFLD combined with T2DM."

Journal • Diabetes • Dyslipidemia • Fibrosis • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

Effects of Exercise and Intensive Vascular Risk Reduction on Cognitive Function in Older Adults: A Randomized Clinical Trial. (PubMed, JAMA Neurol) - P2/3 | "Participants were randomized with a 1:1:1:1 ratio to aerobic exercise training, IRVR (lowering of systolic blood pressure to <130 mm Hg and serum low-density lipoprotein cholesterol with atorvastatin), IRVR + exercise, and usual care...In this multicenter randomized clinical trial among older adults with family history of dementia and/or self-reported subjective cognitive decline, exercise, IRVR, or both did not result in statistically significant differences in improvements in cognitive function over 24 months. ClinicalTrials.gov Identifier: NCT02913664."

Clinical • Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Dyslipidemia • Hypertension

STATIN USE, LDL-C LEVELS, AND COGNITIVE DECLINE IN ALZHEIMER'S DISEASE: A SWEDISH REGISTRY-BASED COHORT STUDY (ADPD 2026) - "Statin use (simvastatin, atorvastatin, or rosuvastatin) was modeled as a time-varying exposure based on prescription data. Statin use, particularly simvastatin, was associated with slower cognitive decline among AD patients, especially those with higher LDL-C levels. These findings suggest that both statin therapy and lipid status may jointly influence cognitive trajectories in AD."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Dyslipidemia

LIPOPHILIC STATINS AND RISK OF PARKINSON'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS (ADPD 2026) - "While lipophilic statins overall did not significantly affect PD risk; certain lipophilic statins like simvastatin, lovastatin and atorvastatin, showed a significant protective effect. Further research is needed to confirm the neuroprotective potential and clinical applications of statins."

Retrospective data • Review • CNS Disorders • Dyslipidemia • Movement Disorders • Parkinson's Disease

AN UNUSUAL CASE OF CEREBELLAR ISCHEMIC STROKE INITIALLY PRESENTING AS ISOLATED HEMIFACIAL SPASM WITHOUT OTHER NEUROLOGICAL SYMPTOMS AND SIGNS (ADPD 2026) - "For now, we report for the first time a rare manifestation of cerebellar ischemic stroke initially presenting isolated hemifacial spasm without other neurological symptoms and signs. As like this case, if there are abrupt-onset isolated hemifacial spasm, it should be considered diagnosis of cerebellar ischemic stroke."

Clinical • Cardiovascular • Ischemic stroke

Lanadelumab in Children with Hereditary Angioedema Aged 2 to <12 Years: Results of the TAHORA Study Feasibility Assessment (EAACI 2026) - No abstract available

Clinical • Immunology

Clinical differences between elderly and non-elderly chronic subdural hematoma patients. (PubMed, Front Neurol) - "Moreover, the hematoma was thicker and larger, the usage of atorvastatin was more common, the recurrence rate was higher, and the mean hospital stay was longer in elderly CSDH patients than in non-elderly CSDH patients (all P < 0.05). Elderly CSDH patients were less likely to have the traumatic events and more likely to have the history of taking anticoagulants/antiplatelet drugs, who were also owing the higher rate of using atorvastatin and hematoma recurrence, compared to non-elderly CSDH patients."

Journal • CNS Disorders • Geriatric Disorders

UNVEILING FAMILIAL SITOSTEROLEMIA: A SILENT CULPRIT BEHIND HYPERLIPIDEMIA IN AN ASYMPTOMATIC 28 YEAR-OLD MALE (ACC 2026) - "Decision-Making: Atorvastatin 80 mg was initiated but reduced to 40 mg due to myalgias, and ezetimibe was added...A trial of evolocumab, a PCSK9 inhibitor, was ineffective (LDL 455 mg/dL)... FS should be considered in young patients with refractory hyperlipidemia. Genetic testing and targeted therapy with ezetimibe, alongside dietary phytosterol restriction, can achieve significant LDL reduction and prevent cardiovascular complications."

Coronary Artery Disease • Dyslipidemia • Hypertension • Metabolic Disorders • Musculoskeletal Pain

CHRONOLOGICAL AGING AND PROGRESSION OF CORONARY ARTERY DISEASE: INSIGHTS FROM POOLED IVUS TRIALS OF LIPID-LOWERING THERAPIES (ACC 2026) - " Patient-level data from five IVUS trials [REVERSAL, ASTEROID, SATURN, ILLUSTRATE (atorvastatin arm only), and GLAGOV (evolocumab arm only)]. In this large pooled IVUS analysis of patients treated with statins or PCSK9 inhibitors, chronological age did not influence the degree of coronary plaque regression. Chronological age alone should not be used to preclude the use of intensive lipid-lowering therapies in older adults at high cardiovascular risk."

Acute Coronary Syndrome • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Hypertension • CRP

Efficacy of Statins in Adjunctive Treatment of Vitiligo: A Systematic Review and Meta-Analysis (AAD 2026) - "The trials assessed simvastatin or atorvastatin, administered orally in 75% and topically in 25%. Statins should not replace standard therapies but may serve as adjuncts pending further validation. Future trials must improve methodological quality and clarify patient subgroups most likely to benefit."

Retrospective data • Review • Dermatology • Immunology • Vitiligo

A Preclinical study on Protective Effects of Atorvastatin Against Methotrexate-Induced Hepato-Renal Toxicity: Role of Oxidative Stress and Inflammation (APASL 2026) - No abstract available

Oxidative stress • Preclinical • Inflammation